Continuous Glucose Monitoring Time-in-Range and HbA<sub>1c</sub> Targets in Pregnant Women with Type 1 Diabetes
Tundidor et al.
The finding, in our words
In pregnant women with type 1 diabetes, target attainment for continuous glucose monitoring and HbA1c remained low throughout gestation but improved with real-time continuous glucose monitoring, which was associated with reduced risk of adverse perinatal outcomes.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Transitioning from SMBG to rtCGM while using the mySugr app improved glycaemic control across the cohort, with benefits sustained over six months; new users of the app showed the greatest improvements, and people with type 1 diabetes experienced a larger reduction in glucose variability whereas those with type 2 showed a relatively larger decrease in average glucose.
In a crossover trial of 23 adults with newly diagnosed type 2 diabetes, a personalised diet based on predicted postprandial glucose responses improved continuous glucose monitoring measures significantly more than a Mediterranean diet, including lower average postprandial glucose response and less time in hyperglycaemia. A six-month follow-up of the personalised diet further improved glycaemic control and metabolic health, supporting its clinical utility for decentralised diabetes management.
A fully remote decentralised clinical trial in Danish adults with type 2 diabetes demonstrated operational feasibility with rapid recruitment, high retention (87 percent), and excellent adherence to continuous glucose monitoring (95 percent achieving ≥70 percent data coverage) and telemedicine visits (97 percent). Activity tracker adherence was poor (12 percent) due to technical issues, but remote safety monitoring was effective with no unexpected adverse events, supporting the viability of remote diabetes management.
In adults with type 1 diabetes, Dexcom G7 and FreeStyle Libre 3 showed high accuracy during physical activity, whereas the Simplera system was less accurate; this matters for selecting devices in decentralised monitoring.
Sanfilippo et al., Diabetes, obesity & metabolism · source ↗
This review indicates that poor glycaemic control and increased glucose variability are associated with worse oncologic outcomes and reduced treatment efficacy in cancer patients with diabetes. Continuous glucose monitoring is highlighted as a superior tool to HbA1c for capturing dynamic glucose fluctuations, potentially improving treatment tolerance and adherence.
Ruggeri et al., Reviews in endocrine & metabolic disorders · source ↗